



Dr. med. Georg Gasteiger

Institute of Medical Microbiology and Hygiene
and FZI Research Center for Immunotherapy
University of Mainz Medical Center

Date of birth: April 25th, 1976, in Freising
Family status: 1 child, born 2015



Professional Experience

- Since 1/2015 Emmy Noether Group Leader
Institute of Medical Microbiology and Hygiene, University of
Mainz Medical Center
- 2010 – 2014 Postdoctoral Scientist, Memorial Sloan-Kettering Cancer Center
and Howard Hughes Medical Institute, Immunology Program,
New York, USA
- 2004 – 2010 Physician Scientist in Microbiology and Virology, Technische
Universität München (TUM) and Helmholtz Zentrum München

Education and Clinical Training

- 2004 – 2009 Specialization in Microbiology, Virology and Epidemiology of
Infectious Diseases
Board Certification (“Facharztanerkennung”) in 11/2009
- 2004 – 2008 Doctoral Thesis, Institute of Virology, TUM
- 1997 – 2004 Medical School, TUM and LMU Munich
Rotations in Buenos Aires, Madrid, La Reunion, Vienna and New
York

Scientific Expertise

Immunology of Infectious and Inflammatory Diseases
Innate Lymphoid Cells & NK Cells, T cells, Regulatory T cells

Current External Funding

Emmy Noether Young Investigators Programme, (2015-2017/2020, 1.460.000 Euro)
Roche Postdoctoral Fellowship Programm, (2015-2017, 276.000 CHF)

Awards, Honors and Grants

Helmholtz Young Investigators Award, Berlin/Munich (2014-2019, 1.250.000 Euro,
not accepted)
Irvington Fellowship of the Cancer Research Institute, New York (2012-2015,
165.000 USD)

Member of the FZI

Fellowship for the RIKEN RCAI International Summer Program, Yokohama (2010)
Helmholtz Fellow at the Lindau Nobel Laureate Meeting (2010)
Distinction "*summa cum laude*" for the doctoral thesis, Faculty of Medicine, TUM (2008)

Languages

English: fluent in technical/scientific and common English
Spanish: fluent, DELE test, Universidad de Salamanca / Instituto Cervantes
French: basic knowledge

Publications

Total Number Publications: 26 (8 First Authorships, 16 Co-Authorships, 2 Review Articles)
Cumulative Impact Factors: 290.9

Selected Publications:

1. **Gasteiger G[#]**, Fan D^{*}, Dikyi S, Lee SY and Rudensky AY[#] (2015) Tissue residency of innate lymphoid cells in lymphoid and non-lymphoid organs. Science 2015 Oct; epub [#] corresponding authors
2. Lu LF^{*}, **Gasteiger G^{*}**, Yu IS, Chaudhry A, Bos P, Lin L, Zawislak C, Cho S, Sun JC, Lin SW, Rudensky AY (2015) A single miRNA-mRNA interaction affects the immune response in a context- and cell type-specific manner. Immunity 43: 52-64 ^{*} corresponding authors
3. **Gasteiger G[#]**, Rudensky AY[#] (2014) Interactions between innate and adaptive lymphocytes, Nat Rev Immunol 14: 631-9 [#] corresponding authors
4. Feng Y, Arvey A, Chinen T, Van der Veen J, **Gasteiger G**, Rudensky AY (2014) Maintenance of regulatory T cell identity by a dedicated cis element in the Foxp3 locus. Cell 158: 749-63
5. Geiger TL, Abt MC^{*}, **Gasteiger G^{*}**, van den Brink MR, Pamer EG, Hanash AM, Sun JC (2014) Nfil3 is crucial for development of innate lymphoid cells and host protection against intestinal pathogens. J Exp Med 211: 1723-31
6. **Gasteiger G**, Hemmers S, Firth MA, Le Floch A, Huse M, Sun JC, and Rudensky AY (2013) IL-2 dependent tuning of NK cell sensitivity for target cells controlled by regulatory T cells. J Exp Med 210: 1167-78
7. **Gasteiger G**, Hemmers S, Bos P, Sun JC, Rudensky AY (2013) IL-2 dependent adaptive control of NK cell homeostasis. J Exp Med 210: 1179-87
8. Kastenmuller W^{*}, **Gasteiger G^{*}**, Subramanian N, Sparwasser T, Busch DH, Belkaid Y, Drexler I, Germain RN (2011) Regulatory T cells selectively control CD8⁺ T cell effector pool size via IL-2 restriction. J Immunol 187: 3186-97.
9. **Gasteiger G^{*}**, Kastenmuller W^{*}, Ljapoci R, Sutter G, Drexler I (2007) Crosspriming of Cytotoxic T-cells Dictates Antigen Requisites for MVA Vector Vaccines. J Virol 81: 11925-36.
10. Kastenmuller W^{*}, **Gasteiger G^{*}**, Gronau J, Baier R, Ljapoci R, Busch DH, Drexler I (2007) Cross-competition of CD8⁺ T-cells shapes the immunodominance hierarchy during boost vaccinations. J Exp Med 204: 2187-98.